Twist Bioscience Corporation $TWST Holdings Lifted by HighMark Wealth Management LLC

Key Points

• HighMark Wealth Management LLC significantly increased its holdings in Twist Bioscience Corporation by 12,127% during Q2 2023, now owning over 38,500 shares valued at approximately $1.4 million.
• Twist Bioscience's stock rose 4.9% recently, reaching $30.68, with a market capitalization of $1.85 billion and a P/E ratio of -21.16.
• Equities research analysts have mixed opinions on the stock, with a consensus rating of "Moderate Buy" and a target price of $48.90, despite one recent downgrade from Barclays to $40.

HighMark Wealth Management LLC increased its holdings in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 12,127.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,515 shares of the company's stock after acquiring an additional 38,200 shares during the period. Twist Bioscience comprises about 0.7% of HighMark Wealth Management LLC's holdings, making the stock its 20th largest holding. HighMark Wealth Management LLC owned approximately 0.06% of Twist Bioscience worth $1,417,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of TWST. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after purchasing an additional 302 shares during the period. Voya Investment Management LLC boosted its holdings in shares of Twist Bioscience by 2.2% during the first quarter. Voya Investment Management LLC now owns 161,531 shares of the company's stock worth $6,342,000 after purchasing an additional 3,539 shares during the period. Hodges Capital Management Inc. purchased a new position in Twist Bioscience during the first quarter valued at approximately $344,000. Rhumbline Advisers increased its stake in Twist Bioscience by 5.0% in the 1st quarter. Rhumbline Advisers now owns 95,964 shares of the company's stock valued at $3,768,000 after buying an additional 4,571 shares during the period. Finally, Strs Ohio acquired a new position in Twist Bioscience in the 1st quarter valued at approximately $711,000.

Twist Bioscience Stock Up 4.9%

Twist Bioscience stock opened at $30.68 on Friday. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 1-year low of $24.07 and a 1-year high of $55.33. The firm's fifty day simple moving average is $28.02 and its 200-day simple moving average is $33.11. The company has a market capitalization of $1.85 billion, a P/E ratio of -21.16 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The firm had revenue of $96.06 million for the quarter, compared to the consensus estimate of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on TWST shares. Barclays decreased their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a research note on Thursday. Evercore ISI set a $46.00 price objective on Twist Bioscience in a report on Monday, August 4th. Finally, Cowen restated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Twist Bioscience currently has a consensus rating of "Moderate Buy" and a consensus target price of $48.90.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 2,449 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total transaction of $93,429.35. Following the transaction, the chief financial officer owned 103,569 shares in the company, valued at $3,951,157.35. This trade represents a 2.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Emily M. Leproust sold 2,265 shares of Twist Bioscience stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $25.76, for a total transaction of $58,346.40. Following the completion of the transaction, the chief executive officer directly owned 634,740 shares in the company, valued at approximately $16,350,902.40. This represents a 0.36% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,436 shares of company stock worth $251,632. 3.01% of the stock is currently owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.